In the REDEFINE 1 phase 3a trial, semaglutide at a dose of 2.4 mg with cagrilintide at a dose of 2.4 mg led to significant body weight reduction in adults without diabetes and Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data Current Obesity Reports Springer Nature Link Beyond semaglutide and tirzepatide, where might we find the next GLP 1 based advances in #weightloss #obesity Take a look at the slope of the lines for the combination of cagrilintide + semaglutide and Tirzepatide Dosage Calculator and Chart A Z Guide Cagrilintide Dosage Calculator and Chart